$ANAB
ANAPTYSBIO, INC Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000137005322000009 Filed on March 07, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$1.011M	$63.18M	$60.00M
YoY Change	-98.32%	-15.77%	1900.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.392M	$21.49M	$5.090M
YoY Change	5.93%	14.02%	32.9%
% of Gross Profit
Research & Development	$26.78M	$98.50M	$21.57M
YoY Change	24.14%	23.08%	0.65%
% of Gross Profit
Depreciation & Amortization	$165.0K	$619.0K	$140.0K
YoY Change	17.86%	10.73%	0.0%
% of Gross Profit
Operating Expenses	$32.17M	$120.0M	$26.66M
YoY Change	20.66%	21.35%	5.54%
Operating Profit		-$56.81M
YoY Change		137.92%
Interest Expense	$68.00K	$0.00	$380.0K
YoY Change	-82.11%		-81.73%
% of Operating Profit
Other Income/Expense, Net	-$1.449M	-$982.0K	-$80.00K
YoY Change	1711.25%	-124.87%	-27.27%
Pretax Income	-$32.54M	-$57.80M	$33.65M
YoY Change	-196.7%	189.98%	-265.85%
Income Tax		$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$32.54M	-$57.80M	$33.65M
YoY Change	-196.7%	189.98%	-266.09%
Net Earnings / Revenue	-3218.4%	-91.49%	56.08%
Basic Earnings Per Share		-$2.11
Diluted Earnings Per Share	-$1.182M	-$2.11	$1.230M
COMMON SHARES
Basic Shares Outstanding	27.51M shares	27.43M shares	27.35M shares
Diluted Shares Outstanding		27.43M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$548.1M	$548.1M	$393.7M
YoY Change	39.23%	39.22%	5.19%
Cash & Equivalents	$495.7M	$495.7M	$250.5M
Short-Term Investments	$52.37M	$52.37M	$143.2M
Other Short-Term Assets	$4.903M	$4.903M	$2.900M
YoY Change	69.07%	69.07%	-17.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$553.9M	$553.9M	$396.6M
YoY Change	39.67%	39.66%	4.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.283M	$21.84M	$1.783M
YoY Change	28.04%	940.05%	10.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$67.10M	$67.10M	$17.50M
YoY Change	283.41%	283.41%	-67.77%
Other Assets	$256.0K	$256.0K	$258.0K
YoY Change	-0.78%	-14.67%	-82.58%
Total Long-Term Assets	$89.19M	$89.19M	$19.99M
YoY Change	346.17%	345.97%	-65.21%
TOTAL ASSETS
Total Short-Term Assets	$553.9M	$553.9M	$396.6M
Total Long-Term Assets	$89.19M	$89.19M	$19.99M
Total Assets	$643.1M	$643.1M	$416.6M
YoY Change	54.38%	54.36%	-4.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.741M	$1.741M	$4.217M
YoY Change	-58.71%	-58.55%	-74.03%
Accrued Expenses	$12.85M	$14.36M	$15.26M
YoY Change	-15.78%	-7.96%	38.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$16.10M	$16.10M	$19.82M
YoY Change	-18.78%	-18.69%	-32.89%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$270.5M	$270.5M	$0.00
YoY Change			-100.0%
Total Long-Term Liabilities	$270.5M	$270.5M	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.10M	$16.10M	$19.82M
Total Long-Term Liabilities	$270.5M	$270.5M	$0.00
Total Liabilities	$286.6M	$286.6M	$19.82M
YoY Change	1346.15%	1347.69%	-34.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$321.8M		-$264.0M
YoY Change	21.9%		8.17%
Common Stock	$28.00K		$27.00K
YoY Change	3.7%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$356.4M	$356.4M	$396.7M
YoY Change
Total Liabilities & Shareholders Equity	$643.1M	$643.1M	$416.6M
YoY Change	54.38%	54.36%	-4.28%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$32.54M	-$57.80M	$33.65M
YoY Change	-196.7%	189.98%	-266.09%
Depreciation, Depletion And Amortization	$165.0K	$619.0K	$140.0K
YoY Change	17.86%	10.73%	0.0%
Cash From Operating Activities	-$25.30M	-$45.92M	$37.58M
YoY Change	-167.33%	224.36%	-337.7%
INVESTING ACTIVITIES
Capital Expenditures	-$14.00K	$1.366M	-$310.0K
YoY Change	-95.48%	140.07%	181.82%
Acquisitions
YoY Change
Other Investing Activities	-$66.68M	$40.20M	$3.900M
YoY Change	-1809.74%	-57.7%	-5.8%
Cash From Investing Activities	-$66.69M	$38.84M	$3.600M
YoY Change	-1952.61%	-58.89%	-10.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.553M
YoY Change		414.72%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	251.3M	$252.3M	130.0K
YoY Change	193235.38%	-28802.84%	-218.18%
NET CHANGE
Cash From Operating Activities	-25.30M	-$45.92M	37.58M
Cash From Investing Activities	-66.69M	$38.84M	3.600M
Cash From Financing Activities	251.3M	$252.3M	130.0K
Net Change In Cash	159.3M	$245.2M	41.31M
YoY Change	285.72%	208.68%	-447.43%
FREE CASH FLOW
Cash From Operating Activities	-$25.30M	-$45.92M	$37.58M
Capital Expenditures	-$14.00K	$1.366M	-$310.0K
Free Cash Flow	-$25.29M	-$47.29M	$37.89M
YoY Change	-166.74%	221.11%	-341.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20211231#CollaborationRevenueMember
CY2019	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20211231#CollaborationRevenueMember
CY2020	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20211231#CollaborationRevenueMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37985
CY2021	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	us-gaap	Assets Current AssetsCurrent	396561000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	USD
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3828755
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	10770 Wateridge Circle
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2021	dei	City Area Code CityAreaCode	858
CY2021	dei	Local Phone Number LocalPhoneNumber	362-6295
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
CY2021	dei	Trading Symbol TradingSymbol	ANAB
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	489310431	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27672428	shares
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	495729000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	250456000	USD
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	876000	USD
CY2020Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	0	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	52368000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	143197000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4903000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2908000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	553876000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1783000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19558000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	344000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	67097000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	17546000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	258000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2021Q4	us-gaap	Assets Assets	643070000	USD
CY2020Q4	us-gaap	Assets Assets	416552000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1741000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4217000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15262000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1505000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	342000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16099000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19821000	USD
CY2021Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	251093000	USD
CY2020Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19450000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	153000	USD
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27647000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27647000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27356000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27356000	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	678575000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	660665000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-422000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321753000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263957000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396731000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	643070000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	416552000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63175000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	75000000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8000000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	98496000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	80025000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99338000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21493000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18854000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16094000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-23879000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-107432000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	119989000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	98879000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	115432000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-56814000	USD
CY2021	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Interest Expense InterestExpense	0	USD
CY2019	us-gaap	Interest Expense InterestExpense	1041000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	431000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	3959000	USD
CY2019	us-gaap	Interest Income Other InterestIncomeOther	10984000	USD
CY2021	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	1450000	USD
CY2020	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	USD
CY2019	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	37000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-11000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-982000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3948000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9944000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57796000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19931000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97488000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-152000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-57796000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19931000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-418000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-96775000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-342000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	561000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58214000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20273000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.11
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.11
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.73
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.73
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.60
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.60
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27431000	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27431000	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27302000	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27302000	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27059000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27059000	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	486365000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3007000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	12411000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	561000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	405008000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	497000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	11499000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-342000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19931000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396731000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2564000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	15347000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-418000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-97336000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	619000	USD
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	893000	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1450000	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-676000	USD
CY2021	anab	Gain Loss On Disposal Of Property And Equipment Net Of Gain On Lease Termination GainLossOnDisposalOfPropertyAndEquipmentNetOfGainOnLeaseTermination	15000	USD
CY2020	anab	Gain Loss On Disposal Of Property And Equipment Net Of Gain On Lease Termination GainLossOnDisposalOfPropertyAndEquipmentNetOfGainOnLeaseTermination	-26000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-57796000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-57796000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-19931000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	559000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	514000	USD
CY2021	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	15347000	USD
CY2020	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	11499000	USD
CY2019	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	12411000	USD
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-493000	USD
CY2020	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-461000	USD
CY2019	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	2633000	USD
CY2021	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1471000	USD
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1058000	USD
CY2021	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2020	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2019	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-174000	USD
CY2019	anab	Gain Loss On Disposal Of Property And Equipment Net Of Gain On Lease Termination GainLossOnDisposalOfPropertyAndEquipmentNetOfGainOnLeaseTermination	0	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	876000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1801000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1048000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3580000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4740000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-7694000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13203000	USD
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-72000	USD
CY2020	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1183000	USD
CY2019	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-999000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45920000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14157000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69517000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	118662000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	194927000	USD
CY2019	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	251815000	USD
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	158848000	USD
CY2019	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	0	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	289971000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	384051000	USD
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1366000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	569000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	805000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38835000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	94475000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	131431000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2553000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	496000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3007000	USD
CY2021	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	250000000	USD
CY2020	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	0	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1375000	USD
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	7500000	USD
CY2021	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	255000	USD
CY2020	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	0	USD
CY2019	anab	Payments Of Advance Future Royalties Issuance Costs PaymentsOfAdvanceFutureRoyaltiesIssuanceCosts	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	252298000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-879000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4493000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	245213000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79439000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57421000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250516000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171077000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	113656000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495729000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250516000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	171077000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	424000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20685000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2295000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	279000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	41000	USD
CY2021	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	11000	USD
CY2020	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	0	USD
CY2019	anab	Receivable Issuance Of Common Stock Stock Options Exercised ReceivableIssuanceOfCommonStockStockOptionsExercised	0	USD
CY2021	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	102000	USD
CY2020	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	0	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	60000	USD
CY2019	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business <div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications. We develop our product candidates using our proprietary antibody discovery technology platform, which is based upon a breakthrough understanding of the natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We currently generate revenue from milestones and royalties achieved under our collaborative research and development arrangements. </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common and preferred stock, royalty monetization, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months from the issuance of our consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Certain reclassifications have been made to 2020 and 2019 financial information to conform to the current year presentation of other long-term assets, operating lease right-of-use, or “ROU” asset, and operating lease liabilities on the Consolidated Balance Sheets and Consolidated Statements of Cash Flows.
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.</span></div>
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents and certain investments in money market funds, certificates of deposit, agency securities, commercial obligations and U.S. Treasury securities. Bank deposits are diversified between three financial institutions and these deposits may exceed insured limits. We are exposed to credit risk in the event of default by the financial institutions holding our cash and cash equivalents and issuers of investments that are recorded on our consolidated balance sheets. We mitigate our risk by investing in high-grade instruments and limiting the concentration in any one issuer, which limits our exposure.</span></div>
CY2021	anab	Number Of Financial Institutions Utilized For Diversification Of Funds NumberOfFinancialInstitutionsUtilizedForDiversificationOfFunds	3	bank
CY2021	us-gaap	Property Plant And Equipment Impairment PropertyPlantAndEquipmentImpairment	Long Lived Assets Long-lived assets, consisting of property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable based on undiscounted cash flows. If long-lived assets are impaired, an impairment loss is recognized and is measured as the amount by which the carrying value exceeds the estimated fair value of the assets.
CY2021	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2020	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2019	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7205000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6728000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4922000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4945000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1783000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4177000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3688000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	569000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	408000	USD
CY2021Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7953000	USD
CY2020Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	10936000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	154000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	230000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15262000	USD
CY2021	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	1500000	USD
CY2020Q4	anab	Advance Future Royalties Liabilities AdvanceFutureRoyaltiesLiabilities	0	USD
CY2021	anab	Proceeds From Advance Future Royalties ProceedsFromAdvanceFutureRoyalties	250000000	USD
CY2021	anab	Advance Future Royalties Issuance Costs AdvanceFutureRoyaltiesIssuanceCosts	357000	USD
CY2021	anab	Amortization Of Advance Future Royalties Issuance Costs AmortizationOfAdvanceFutureRoyaltiesIssuanceCosts	7000	USD
CY2021	anab	Noncash Interest Expense Recognized NoncashInterestExpenseRecognized	1443000	USD
CY2021Q4	anab	Advance Future Royalties Liabilities AdvanceFutureRoyaltiesLiabilities	251093000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	119680000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	217000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	119465000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	160540000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	208000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	160743000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	108694000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	217000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	108694000	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	217000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	46713000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	2399000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	49112000	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5000	USD
CY2021	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0	USD
CY2020	us-gaap	Available For Sale Debt Securities Gross Unrealized Loss AvailableForSaleDebtSecuritiesGrossUnrealizedLoss	0	USD
CY2021Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	USD
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27647250	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27647250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3460295	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7980586	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2920700	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.67
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M14D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	17434000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1105845	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.49
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	272462	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.85
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	293788	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	29.24
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3460295	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42987000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1852668	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.32
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M4D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	27400000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2100000	USD
CY2019	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	12411000	USD
CY2021	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	15347000	USD
CY2020	anab	Sharebased Compensation And Issuance Of Stock And Warrants For Services Or Claims SharebasedCompensationAndIssuanceOfStockAndWarrantsForServicesOrClaims	11499000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1
CY2021	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2021	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	8000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	6000	USD
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Amount DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount	6000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	300000	USD
CY2020Q4	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	100000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2213000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	865000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	879000	USD
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	705000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	938000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	937000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2316000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2386000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2457000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2531000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	2607000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	13239000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25536000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4581000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20955000	USD
CY2021	anab	Collaboration License Agreement Maximum Term CollaborationLicenseAgreementMaximumTerm	P19Y
CY2021	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	200000	USD
CY2020	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	200000	USD
CY2019	anab	Collaboration License Agreement Upfront Milestone And Royalty Expense CollaborationLicenseAgreementUpfrontMilestoneAndRoyaltyExpense	500000	USD
CY2021	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	200000	USD
CY2020	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	300000	USD
CY2019	anab	Payments For Upfront Milestone And Royalty Payments PaymentsForUpfrontMilestoneAndRoyaltyPayments	100000	USD
CY2021Q4	us-gaap	Other Commitment Due In Next Twelve Months OtherCommitmentDueInNextTwelveMonths	700000	USD
CY2021Q4	anab	Other Commitment To Be Paid After Year One OtherCommitmentToBePaidAfterYearOne	200000	USD
CY2021	anab	Collaboration License Agreement Obligation Payable Period CollaborationLicenseAgreementObligationPayablePeriod	P10Y
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-57741000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19832000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-97187000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-55000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-99000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-301000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57796000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19931000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67203000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	57772000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	9527000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-97488000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17614000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	8091000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5329000	USD
CY2021Q4	anab	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	4451000	USD
CY2020Q4	anab	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1201000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	769000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	90473000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81484000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	4154000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	0	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	115000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	150000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4269000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	150000	USD
CY2021Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	86204000	USD
CY2020Q4	anab	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	81334000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	86204000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	81334000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	200000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12138000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4186000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-20473000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-142000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-21000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-377000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-17000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-18000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Exempt Income IncomeTaxReconciliationTaxExemptIncome	-34000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-708000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	871000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1122000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	76000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-11000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Settlements IncomeTaxReconciliationTaxSettlements	-661000	USD
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-34000	USD
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	40000	USD
CY2019	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-53000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-8087000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3389000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4405000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4842000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	6678000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	26905000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-152000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	100000	USD
CY2021	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	900000	USD
CY2021	anab	Effective Income Tax Rate Reconciliation Tax Expense Benefit Employee Stock Purchase Plan Amount EffectiveIncomeTaxRateReconciliationTaxExpenseBenefitEmployeeStockPurchasePlanAmount	0	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	0	USD
CY2020	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	200000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1100000	USD
CY2019	anab	Effective Income Tax Rate Reconciliation Nondeductible Expense Sharebased Compensation Cost Disqualifying Dispositions Of Incentive Stock Options EffectiveIncomeTaxRateReconciliationNondeductibleExpenseSharebasedCompensationCostDisqualifyingDispositionsOfIncentiveStockOptions	300000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4044000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3146000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2555000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	984000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	898000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2473000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4044000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2021	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001370053-22-000009-index-headers.html	Edgar Link	pending
0001370053-22-000009-index.html	Edgar Link	pending
0001370053-22-000009.txt	Edgar Link	pending
0001370053-22-000009-xbrl.zip	Edgar Link	pending
amendmentno4totesaroanapty.htm	Edgar Link	pending
anab-12312021x10kxexx311.htm	Edgar Link	pending
anab-12312021x10kxexx312.htm	Edgar Link	pending
anab-12312021x10kxexx321.htm	Edgar Link	pending
anab-12312021x10kxexx322.htm	Edgar Link	pending
anab-12312021xexx211.htm	Edgar Link	pending
anab-12312021xexx231.htm	Edgar Link	pending
anab-20211231.htm	Edgar Link	pending
anab-20211231.xsd	Edgar Link	pending
anab-20211231_cal.xml	Edgar Link	unprocessable
anab-20211231_def.xml	Edgar Link	unprocessable
anab-20211231_g1.jpg	Edgar Link	pending
anab-20211231_htm.xml	Edgar Link	completed
anab-20211231_lab.xml	Edgar Link	unprocessable
anab-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
ANAPTYSBIO, INC Stock $anab

2021 Q4 Form 10-K Financial Statement

#000137005322000009 Filed on March 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB ANAPTYSBIO, INC Stock $anab

2021 Q4 Form 10-K Financial Statement

#000137005322000009 Filed on March 07, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
ANAPTYSBIO, INC Stock $anab